CORRECTION

In the article entitled, “Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension” (Volume 188, pages 1608–1624 of the July 2018 issue of *The American Journal of Pathology*; <https://doi.org/10.1016/j.ajpath.2018.03.018>), the authors have noted an error in the author affiliations, as well as the correspondence address.

The corrected address and affiliations are as follows:

From the Departments of Medicine* and Nuclear Medicine** and the Divisions of Allergy and Immunology,† Infection,‡ Gastroenterology and Hepatology,†† and General

Medicine,‡‡ Taipei Veteran General Hospital, Taipei City; the Department of Medicine,† National Yang-Ming University School of Medicine, Taipei City; the Chia-Yi Branch of Taichung Veterans General Hospital,§ Chia-Yi City; and Institute of Clinical Medicine,¶ Taipei City, Taiwan

Address correspondence to: Ying-Ying Yang, Ph.D., M.P.H., M.D., Division of Clinical Skills Training, Taipei Veteran General Hospital, No. 201, Section 2, Shipai Rd, Beitou District, Taipei City, Taiwan 11217. E-mail: yanggy@vghtpe.gov.tw.

<https://doi.org/10.1016/j.ajpath.2018.06.007>